MX2022012181A - Metodos y composiciones para tratar cancer. - Google Patents

Metodos y composiciones para tratar cancer.

Info

Publication number
MX2022012181A
MX2022012181A MX2022012181A MX2022012181A MX2022012181A MX 2022012181 A MX2022012181 A MX 2022012181A MX 2022012181 A MX2022012181 A MX 2022012181A MX 2022012181 A MX2022012181 A MX 2022012181A MX 2022012181 A MX2022012181 A MX 2022012181A
Authority
MX
Mexico
Prior art keywords
methods
compositions
treating cancer
ppp2r2a
pkmyt1
Prior art date
Application number
MX2022012181A
Other languages
English (en)
Inventor
Stephen Harrison
Christine Taylor Brew
Michael David Winther
Sourabh Banerjee
Shawn Yost
Original Assignee
Engine Biosciences Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Engine Biosciences Pte Ltd filed Critical Engine Biosciences Pte Ltd
Publication of MX2022012181A publication Critical patent/MX2022012181A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

En la presente se describen métodos y composiciones para tratar cáncer. Los métodos pueden comprender el uso de cantidades terapéuticamente efectivas de uno o más agentes para provocar una diferencia en la expresión o actividad de la proteína cinasa, tirosina/treonina 1 asociada a membrana (PKMYT1) en células de cáncer que son deficientes en la subunidad B alfa reguladora de proteína fosfatasa 2 (PPP2R2A).
MX2022012181A 2020-04-01 2021-03-31 Metodos y composiciones para tratar cancer. MX2022012181A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063003736P 2020-04-01 2020-04-01
PCT/US2021/025230 WO2021202780A2 (en) 2020-04-01 2021-03-31 Methods and compositions for treating cancer

Publications (1)

Publication Number Publication Date
MX2022012181A true MX2022012181A (es) 2023-01-30

Family

ID=77927411

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022012181A MX2022012181A (es) 2020-04-01 2021-03-31 Metodos y composiciones para tratar cancer.

Country Status (9)

Country Link
US (1) US20230149415A1 (es)
EP (1) EP4127722A4 (es)
JP (1) JP2023519931A (es)
KR (1) KR20230017167A (es)
CN (1) CN115769077A (es)
AU (1) AU2021249111A1 (es)
CA (1) CA3173799A1 (es)
MX (1) MX2022012181A (es)
WO (1) WO2021202780A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4388137A1 (en) * 2021-08-19 2024-06-26 Engine Biosciences Pte. Ltd. Compositions and methods for generating synthetic lethality in tumors
WO2023177356A2 (en) * 2022-03-18 2023-09-21 Engine Biosciences Pte. Ltd. Compounds and method for pkmyt1 inhibition

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2651347T3 (es) * 2012-11-28 2018-01-25 Merck Sharp & Dohme Corp. Composiciones y métodos para el tratamiento del cáncer
CA2990835A1 (en) * 2015-06-23 2016-12-29 Case Western Reserve University Compositions and methods for treating cancer

Also Published As

Publication number Publication date
AU2021249111A1 (en) 2022-10-20
WO2021202780A2 (en) 2021-10-07
WO2021202780A3 (en) 2021-11-11
CN115769077A (zh) 2023-03-07
KR20230017167A (ko) 2023-02-03
CA3173799A1 (en) 2021-10-07
US20230149415A1 (en) 2023-05-18
JP2023519931A (ja) 2023-05-15
EP4127722A2 (en) 2023-02-08
EP4127722A4 (en) 2024-05-01

Similar Documents

Publication Publication Date Title
MX2021004639A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
MX2022012181A (es) Metodos y composiciones para tratar cancer.
PH12019501116A1 (en) Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20
MX2022002938A (es) Compuestos inhibidores de la proteína arginina n-metil transferasa 5 (prmt5) cooperativos para metiltioadenosina (mta).
PH12020551180A1 (en) Methods and compositions for therapeutic protein delivery
MX2021003554A (es) Proteinas de union a dll3 y metodos de uso.
MX2024003385A (es) Compuestos de pirazina y usos de los mismos.
MX2021002998A (es) Compuestos de triazolo-pirimidina y usos de los mismos.
MX2020013557A (es) Un esteroide de c21-pirazolilo disustituido con 19-nor c3,3 y métodos de uso del mismo.
BR112016008016B8 (pt) Compostos inibidores de kras g12c, composição farmacêutica compreendendo ditos compostos, métodos para regular a atividade e para preparar uma proteína mutante kras, hras ou nras g12c, método para inibir a proliferação de uma população de células e usos terapêuticos dos ditos compostos
TW200510306A (en) Novel hydroxyindoles, their use as inhibitors of phosphodiesterase 4, and processes for preparing them
MX2022004937A (es) Inhibidores de las cinasas raf.
CR6630A (es) Compuestos de indazol, compuestos farmacologicos y metodos para la intervencion o inhibicion de la proliferacion celular
BR112019001768A2 (pt) moduladores do receptor de spiro-lactamas nmda e usos dos mesmos
PH12021550605A1 (en) Farnesoid x receptor agonists and uses thereof
EA201891913A1 (ru) Улучшенные препараты клеток-предшественников взрослой печени
PH12021551036A1 (en) Anti-liv1 immune cell cancer therapy
JOP20220160A1 (ar) مركبات فعّالة نحو مستقبلات نووية
MX2023001287A (es) Bancos universales de células t específicas de antígeno y métodos de fabricación y uso terapéutico de los mismos.
MX2018009189A (es) Compuestos de anillo de siete miembros de pirimidina.
MX2021013602A (es) Inhibidores de jak.
BR112021021826A8 (pt) Uso de apremilaste e um inibidor da tirosina quinase 2 no tratamento de uma doença ou um transtorno responsivo à inibição da fosfodiesterase tipo 4
MX2022007265A (es) Compuestos activos frente a receptores nucleares.
MX2023012048A (es) Composiciones y metodos para inhibir cetohexoquinasa (khk).
PH12021551047A1 (en) Anti-ptk7 immune cell cancer therapy